$ACOG

Opaleye Management Inc. purchased $423K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 52,900 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.00 ($7.92–$8.00, $0.42M total) across 2 trades over 2026-07-31 to 2026-08-03.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Aug 4, 2026, 8:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Neutral
low confidence
Mentioned
$ACOG
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The newest information is the reported open-market purchase size, price range, and post-transaction share count by Opaleye Management Inc. as an indirect holder/10% owner.

02

Market read

Traders may note the accumulation signal, but there is no accompanying fundamental news, so it is unlikely to drive a sustained repricing by itself.

03

What to watch

The trades occurred over multiple days and the filing provides no rationale; without follow-on disclosures (e.g., new guidance, financing, or major contracts), price impact is likely muted.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-04, covering trades from 2026-07-31 to 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Alpha Cognition Inc. (ACOG).

Company-level read

Ticker impact

$ACOGNeutralLow confidence
Context

Opaleye Management Inc., a 10% owner, filed a Form 4 showing an open-market purchase of 52,900 ACOG shares at about $7.996 average.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is a Form 4 open-market purchase with no 10b5-1 plan and no accompanying company-specific news, so traders typically treat it as low-to-moderate informational value.

Market effects

No sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

Open-market purchases by a 10% owner can reflect liquidity management or portfolio rebalancing rather than a strong forward view.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4 insider transaction disclosure (ACOG).

  • Opaleye Management Inc.

    Reporter on the Form 4, identified as a 10% owner making an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.